1Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000:the global picture[ J]. Eur J Cancer,2001,37 : S4-S66
2Munoz N, Bosch FX, De Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer[ J]. New Eng J Med,2003 ,348 :518-527
3Embers ME, Budgeon LR, Pickel M, et al. Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein [ J ]. Virol, 2002,76 : 9798 -9805
4Bermudez-Humaran LG, Cortes-Perez NG, LeLoir Y, et al.An inducible surface presentation system improves cellular immunity against human papillomavirus type 16 E7 antigen in mice after nasal administration with recombinant lactococci[ J ]. J Med Microbiol,2004 ,53 :427-433
5Devaraj K, Gillison ML. Development of HPV vaccines for HPV-associated head and neck squmaous cell carcinoma[ J ]. Crit Rev Oral Biol Med,2003 ,14 :345-362
6Nardelli-Haefliger D, Wirthner D, Schiller JT, et al. Specific antibody levels at the cervix during the menstrual cycle of women vaccined with human papillomavirus 16 viruslike particles[ J ]. Natl Cancer Inst,2003,95 : 1128-1137
7Mao C, Koutsky LA, Auh KA, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial [ J ]. Obstet Gynecol,2006,107 : 18-27
8Steinbrook R. The potential of human papillomavirus vaccines [ J ]. New Eng J Med,2006,354 : 1109-1112
9Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus ( types 6,11,16 and 18 ) L1 virus-like particle vaccine in young women:a randomized double-blind placebo-controlled muhicentre phase Ⅱ efficacy trial[ J ]. Lancet Oncol,2005 ,6 :256-257
10Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial [ J ]. Lancet,2004,364 : 1731-1732
